


PHARMACEUTICAL 2020

IVERIC bio Inc. Rank 169 of 362





PHARMACEUTICAL 2020

IVERIC bio Inc. Rank 169 of 362

The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 337% points. The greatest weakness of IVERIC bio Inc. is the variable Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -154%, being 149% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	128,624
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,984
Liabilities, Non-Current	0
Other Assets	1,390
Other Compr. Net Income	0
Other Expenses	-111
Other Liabilities	0
Other Net Income	2,302
Property and Equipment	173
Research and Development	39,644
Revenues	0
Selling, General and Administrative Expense	21,628

Output Variable	Value in 1000 USD
Assets	130,187
Liabilities	12,984
Expenses	61,161
Stockholders Equity	117,203
Net Income	-58,859
Comprehensive Net Income	-58,859
Economic Capital Ratio	-154%